PhRMA, and the innovative biopharmaceutical companies that it represents, has serious concerns with the call for legislative action regarding compulsory licensing in the EU and its Member States. While the call for evidence recognizes that compulsory licensing should be a tool of last resort, it suggests that there is a need for a central compulsory licensing mechanism in Europe for use in a potential crisis.
PRM
Pharmaceutical Research and Manufacturers of America
Industry association · United States
2
positions filed
in the 583 files tracked
2
legislative files
of 583 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track Pharmaceutical in PolicySpeak: request access →
Work at Pharmaceutical Research and Manufacturers of America? so we know who speaks for it.
Their record over time
Pharmaceutical Research and Manufacturers of America filed 2 positions between 5 Apr 2022 and 29 Apr 2022, across 2 of the 583 legislative files tracked here.
What they argued
The Pharmaceutical Research and Manufacturers of America, and the innovative biopharmaceuticals companies that they represent, commend the European Commission’s call for the development of a single procedure for the granting of supplementary protection certificates (SPCs) in Europe.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Pharmaceutical Research and Manufacturers of America next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 19.
Is this your organization?
Everything on this page comes from Pharmaceutical Research and Manufacturers of America’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.